David Denning

Biography

 David Denning is a research clinician with expertise in fungal diseases. He manages the National Aspergillosis Centre and The Aspergillus Website. He founded 2 biotech companies; F2G Ltd, an antifungal drug discovery and development company and Myconostica Ltd (now sold to Lab21) which developed and commercialised real-time molecular tests for fungal infections. His research and clinical group undertakes basic research (genomics, pathogenesis and mechanism of antifungal drug resistance), applied laboratory work (antifungal resistance testing and validation in models, models of pathogenesis, molecular diagnostics), and clinical studies (description of the natural history of fungal infection, and therapy studies). He is increasingly interested in global health and the burden of fungal disease internationally.

Research Interest

 Fungal Infectious Diseases